(HGSI) Human Genome Sciences – Bear of the Day

We are downgrading Human Genome Sciences Inc. (HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. The company suffered a wider-than-expected loss due to lower revenues. The most alarming factor was the below-par showing of Human Genome’s recently launched lupus drug, Benlysta.

Following the lackluster showing, we have increased our loss per share estimates for 2011 and 2012. Moreover, management has pushed back its aim of turning profitable by a year to 2014.

In view of these headwinds, we see little reason for investors to hold on to the stock at current levels. Our target price is $10.00.

HUMAN GENOME (HGSI): Free Stock Analysis Report

Zacks Investment Research

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.


Powered by Facebook Comments

Similar Posts: | | Biotechnology | Healthcare

RSS feeds: HGSI | Human Genome Sciences Inc. | Biotechnology | Healthcare |

Other Posts by | RSS Feed for this author